What is HC Wainwright’s Estimate for SGMO FY2024 Earnings?

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities research analysts at HC Wainwright cut their FY2024 earnings estimates for shares of Sangamo Therapeutics in a note issued to investors on Monday, January 27th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will earn ($0.49) per share for the year, down from their previous forecast of ($0.43). HC Wainwright currently has a “Buy” rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.47) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ Q4 2024 earnings at ($0.11) EPS, Q1 2025 earnings at ($0.09) EPS, Q2 2025 earnings at $0.08 EPS, Q3 2025 earnings at ($0.08) EPS, Q4 2025 earnings at $0.01 EPS, FY2025 earnings at ($0.08) EPS, FY2026 earnings at ($0.17) EPS, FY2027 earnings at ($0.02) EPS, FY2028 earnings at $0.19 EPS and FY2029 earnings at $0.42 EPS.

Sangamo Therapeutics (NASDAQ:SGMO) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported $0.04 EPS for the quarter, beating the consensus estimate of ($0.03) by $0.07. The firm had revenue of $49.41 million during the quarter, compared to analyst estimates of $26.55 million. Sangamo Therapeutics had a negative net margin of 257.87% and a negative return on equity of 264.16%. During the same quarter last year, the business posted ($0.34) EPS.

SGMO has been the topic of a number of other reports. Truist Financial cut their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a report on Thursday, January 23rd. Jefferies Financial Group dropped their target price on shares of Sangamo Therapeutics from $7.00 to $3.00 and set a “buy” rating on the stock in a research note on Tuesday, December 31st. Wells Fargo & Company decreased their price target on shares of Sangamo Therapeutics from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Tuesday, December 31st. Barclays upped their price objective on Sangamo Therapeutics from $3.00 to $9.00 and gave the company an “overweight” rating in a research note on Thursday, November 14th. Finally, StockNews.com downgraded Sangamo Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, December 24th. Three equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $5.17.

Sangamo Therapeutics Price Performance

SGMO stock opened at $1.13 on Wednesday. The stock’s fifty day simple moving average is $1.77 and its two-hundred day simple moving average is $1.33. Sangamo Therapeutics has a 1-year low of $0.30 and a 1-year high of $3.18.

Institutional Investors Weigh In On Sangamo Therapeutics

Several institutional investors have recently made changes to their positions in SGMO. Meritage Portfolio Management raised its stake in shares of Sangamo Therapeutics by 8.6% during the 3rd quarter. Meritage Portfolio Management now owns 85,000 shares of the biopharmaceutical company’s stock valued at $74,000 after purchasing an additional 6,740 shares during the period. Shelton Wealth Management LLC bought a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at about $29,000. Wealth Enhancement Advisory Services LLC lifted its holdings in shares of Sangamo Therapeutics by 55.4% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 108,945 shares of the biopharmaceutical company’s stock worth $94,000 after buying an additional 38,850 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its position in shares of Sangamo Therapeutics by 5.5% in the third quarter. Charles Schwab Investment Management Inc. now owns 1,103,326 shares of the biopharmaceutical company’s stock valued at $956,000 after acquiring an additional 57,125 shares during the period. Finally, Sageworth Trust Co purchased a new position in Sangamo Therapeutics during the fourth quarter valued at approximately $61,000. Hedge funds and other institutional investors own 56.93% of the company’s stock.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.